Cancer Therapeutics Drugs Market Analysis

The cancer drugs market is segmented based on therapy type into chemotherapy, immunotherapy, targeted therapies, hormonal therapy, and others, out of which, the targeted therapy segment is anticipated to grab the largest share by the end of 2021 on account of advancement in cellular technology and gene therapy which have contributed to improve the understanding of tumour cells and their metabolism at molecular level, thus driving the need for targeted drug therapies for treatment of cancer.

On the basis of cancer types, the breast cancer drugs segment in the market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that hormones, both in the form of combined hormone replacement therapy and combined oral contraceptives increase the risk of breast cancer.

Our in-depth analysis of the global market includes the following segments:

By Therapy Type	Chemotherapy Immunotherapy Targeted Therapies Hormonal therapy Others
By Cancer type	Blood cancer Lung cancer Gastrointestinal cancer Breast cancer Prostate cancer Bladder cancer Oral cancer Skin cancer Colon cancer Others

Frequently Asked Questions (FAQ)

Greater exposure to risk factors and Growing investment in the development of advanced therapies are the key factors driving market growth.

The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.

Costly therapies and lack of awareness about cancer therapies in low and middle income economic regions are estimated to hamper market growth.

The market in Asia Pacific region will provide ample growth opportunities owing to the increasing awareness about cancer.

The major players dominating the cancer therapeutics drugs market are F. Hoffman-La Roche Ltd, Celgene Corp, Novartis AG, Pfizer Inc, Johnson and Johnson, among others.

Cancer Therapeutics Drugs Market Analysis